Rosie was given months to live after chemotherapy and immunotherapy failed. Several of her tumors later shrank following an experimental personalized mRNA cancer vaccine, but that outcome does not establish that the vaccine caused the change or that it will work for other dogs.
Her owner, Sydney technology entrepreneur Paul Conyngham, used computational genomics and ChatGPT while developing the individualized treatment. The effort has since become Gamgee, a startup running clinical trials in Australia and accepting cases from dog owners globally.
The distinction between a promising response and a proven treatment matters for owners facing a cancer diagnosis. Rosie’s experience offers a reason to study the approach, not evidence of a cure.
How the personalized vaccine is made
The process begins with DNA sequencing of a dog’s tumor and healthy tissue. Comparing those samples allows analysts to identify mutations associated with the cancer rather than the dog’s healthy cells.
In Rosie’s case, ChatGPT-assisted analysis helped prioritize mutations thought likely to produce proteins that her immune system could recognize. Scientists at the University of New South Wales RNA Institute then synthesized an mRNA sequence intended to teach her immune system to identify and attack cells carrying the selected mutations.
Gamgee says its current process starts with a veterinary referral and an eligibility review. Tissue sampling, genomic sequencing, computational target selection and individualized manufacturing follow, with the finished vaccine administered by a veterinarian.
On its veterinary information page, the company describes an estimated four-week path from referral to delivery. That estimate is based on its first case, and Gamgee says sequencing and manufacturing schedules can vary.
Conyngham announced Gamgee on Aug. 11, 2026, after the project attracted attention earlier in the year. The company joined Y Combinator’s Summer 2026 batch and is conducting Australian clinical trials. Pricing and detailed availability information had not been publicly disclosed.
What Rosie’s response cannot prove
Several tumors shrinking is a measurable and important outcome, but a single case cannot determine why it happened. The available information does not establish that Rosie was cured, and it does not separate the vaccine’s possible effect from other explanations.
An oncologist writing in The Conversation identified several limitations that controlled research must address. Tumors can occasionally regress for reasons unrelated to a new treatment, while delayed effects from previous care can complicate interpretation.
Cancer also varies by tumor type, mutation pattern and immune response. A target that appears promising during genomic analysis may not produce an effective immune attack in the individual dog.
That uncertainty is not unique to this project. A 2024 veterinary immunotherapy review described unpredictable clinical effectiveness and potential side effects as continuing challenges across canine cancer immunotherapy. The review also noted that results for some earlier canine cancer-vaccine approaches have not remained consistent across later studies.
Controlled trials involving multiple dogs and appropriate comparison groups are therefore essential. Researchers need reproducible evidence showing that treated dogs fare differently from comparable dogs that do not receive the vaccine, along with results broken down by cancer type and other relevant clinical factors.
Questions owners should ask
Owners considering a trial should ask their veterinarian or veterinary oncologist for the written study design, eligibility criteria and participating sites. Other important details include the cancers being studied, enrollment target, comparison groups, primary endpoints and the length of follow-up.
Safety information is equally important. The available details do not identify Gamgee’s known or anticipated adverse effects, monitoring requirements or contraindications, so owners should request those trial-specific facts rather than rely on safety findings from unrelated mRNA vaccines.
They should also ask how investigators will measure tumor response and distinguish it from spontaneous regression or delayed effects of previous treatment. A clear plan for tracking adverse events, disease progression and longer-term outcomes is necessary to understand both potential benefit and risk.
Rosie’s tumor shrinkage created a possible new direction after earlier treatments failed, and the Australian trials may begin answering whether that response can be repeated. Until controlled comparative data and detailed safety findings are available, Gamgee’s vaccine remains an experimental option rather than a proven cure.
What would you do if your dog were in this situation? Share your thoughts in the comments.
By Sarah Mitchell — 8 years as a local-news reporter covering animal welfare, shelters, neighborhood disputes, and public-safety pet stories.
